Prolium Bioscience Launches with $50 Million and Announces First Patients Dosed with PRO-203, a Potential Best-in-Class CD20xCD3 T-Cell Engager, for Severe Autoimmune Disease

Initial $50M Series A investment from founding investor RTW Investments Proceeds will fund clinical development of PRO-203 in systemic sclerosis (SSc) and multiple additional severe autoimmune ...
Morningstar

Nordic Bioscience announces PRO-C3 launched by Roche Diagnostics on cobas analysers

HERLEV, Denmark , May 8, 2025 /PRNewswire/ -- Nordic Bioscience announces that its PRO-C3 test is launched by Roche Diagnostics on their cobas analysers. The Roche Elecsys® PRO-C3, used with the ADAPT ...